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Abstract
Introduction: Increased mammographic breast density is one of the strongest risk factors for breast cancer. While
two-thirds of the variation in mammographic density appears to be genetically influenced, few variants have been
identified. We examined the association of inherited variation in genes from pathways that mediate cell division
with percent mammographic density (PMD) adjusted for age, body mass index (BMI) and postmenopausal
hormones, in two studies of healthy postmenopausal women.
Methods: We investigated 2,058 single nucleotide polymorphisms (SNPs) in 378 genes involved in regulation of
mitosis for associations with adjusted PMD among 484 unaffected postmenopausal controls (without breast
cancer) from the Mayo Clinic Breast Cancer Study (MCBCS) and replicated the findings in postmenopausal
controls (n = 726) from the Singapore and Sweden Breast Cancer Study (SASBAC) study. PMD was assessed in
both studies by a computer-thresholding method (Cumulus) and linear regression approaches were used to
assess the association of SNPs and PMD, adjusted for age, BMI and postmenopausal hormones. A P-value
threshold of 4.2 × 10-5 based on a Bonferroni correction of effective number of independent tests was used for
statistical significance. Further, a pathway-level analysis was conducted of all 378 genes using the self-contained
gene-set analysis method GLOSSI.
Results: A variant in PRPF4, rs10733604, was significantly associated with adjusted PMD in the MCBCS (P = 2.7 ×
10-7), otherwise, no single SNP was associated with PMD. Additionally, the pathway analysis provided no evidence
of enrichment in the number of associations observed between SNPs in the mitotic genes and PMD (P = 0.60). We
evaluated rs10733604 (PRPF4), and 73 other SNPs at P < 0.05 from 51 genes in the SASBAC study. There was no
evidence of an association of rs10733604 (PRPF4) with adjusted PMD in SASBAC (P = 0.23). There were, however,
consistent associations (P < 0.05) of variants at the putative locus, LOC375190, Aurora B kinase (AURKB), and Mini-
chromosome maintenance complex component 3 (MCM3) with adjusted PMD, although these were not statistically
significant.
Conclusions: Our findings do not support a role of inherited variation in genes involved in regulation of cell
division and adjusted percent mammographic density in postmenopausal women.
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Introduction
Mammographic density is a trait that represents the
proportion of stromal and epithelial tissues in a radio-
graphic image of the breast. Women with >50% dense
tissue are at an estimated four- to six-fold increased risk
of breast cancer relative to those with <10% [1,2].
Little is known about the biology of mammographic
density or the mechanisms underlying the association
between density and breast cancer. However, there is
mounting evidence that genetic influences account for a
large proportion of variation in mammographic density
[3-5]. Indeed, it has been estimated that 61% to 67% of
the variation in percent mammographic density adjusted
for age and covariates, may be attributable to genetics
[3]. To date, few loci have been shown associated with
the mammographic density measures that predict breast
cancer [6]. A recent study by Odefrey and colleagues [7]
confirmed the association of a variant (rs3817198) in
lymphocyte-specific protein 1, LSP1, with mammo-
graphic density. Importantly, this variant was initially
identified as a breast cancer susceptibility locus [8].
Also, the first meta-analysis of genome-wide association
studies of adjusted percent mammographic density iden-
tified an association with rs10995190 in ZNF365 [9],
which has also been shown to be a risk factor for breast
cancer [10]. Although these loci are promising, they
explain little variation in the density measures and sug-
gest other genetic variation for mammographic density
remains to be determined.
Mammographic density has been hypothesized to
reflect the cumulative exposure of breast stroma and
epithelium to hormones and growth factors that can sti-
mulate cell division and proliferation [11]. Evidence for
this can be seen in the multiple studies showing positive
associations of mammographic density with use of post-
menopausal hormone therapy (PMH), especially estrogen
and progesterone therapy [12-19], as well as with circu-
lating IGF-1 (in premenopausal women) [20-23], both of
which have been shown to exert proliferative effects on
the breast. In one study of PMH, density, and tissue char-
acteristics, PMH was associated with increased density,
greater fibrous stroma, and less complex lobule type
(lobule type 1), independent of estrogen and progester-
one receptor up-regulation [24]. Increased density was
also associated with Ki67 activity in the ducts and lobules
[24], although this has not been confirmed in the major-
ity of other studies [25-28]. These findings are consistent
with the evidence that fibrous stroma differentiates dense
and non-dense breast tissue [28-32]. Recent histologic
studies that have compared targeted regions of dense and
non-dense tissue in healthy patients suggest the propor-
tion of connective tissue and relative cellularity of stro-
mal cells is higher in dense vs. non-dense areas of the
breast; this was not consistently seen or was seen to a
lesser extent for the epithelial tissues [28,33]. We have
also shown increased aromatase expression in stromal
cells from dense vs. non-dense areas of the breast, which
could result in increased production of estrogens, and
consequent stimulation of cellular proliferation [34].
Furthermore, stromal cells can produce growth factors
such as IGF-1 that may also stimulate proliferation
through paracrine mechanisms [24,35].
Genes involved in regulation of cell division or mitosis
could mediate the influence of these endogenous and
exogenous exposures on breast tissue, reflected in varia-
tions in mammographic density. For instance, virgin
Sprague-Dawley rats treated with the placental hormone
human chorionic gonadotropin (hCG) to mimic preg-
nancy show unique genomic signatures, including
expression of genes involved in cell division control,
which were not seen in rats receiving 17beta-estradiol
and progesterone [36]. In addition, non-epithelial
nuclear area, which may represent increased nuclear size
due to failed or delayed cell division, has been associated
with mammographic breast density in women over age
50 [37]. Here we present a comprehensive analysis of
the association between variation in 378 genes involved




The Mayo Clinic Breast Cancer Study (MCBCS) is an
on-going clinic-based case-control study initiated in
February 2001 at Mayo Clinic, Rochester, MN. Details
of the study design and data collection procedures have
been previously described [38]. Briefly, cases were
women over age 20 years with histologically confirmed
primary invasive breast carcinoma enrolled within six
months of the date of diagnosis. Controls without prior
history of cancer (other than non-melanoma skin can-
cer) were matched on age (± 5 years) and region of resi-
dence to cases. Controls were selected from the
outpatient clinic in the Department of Internal Medicine
at Mayo Clinic where they were seen for general medi-
cal examinations. A self-administered risk factor ques-
tionnaire, blood sample, permission to obtain
mammograms and written informed consent were
obtained from all participants. Case participation was
69% (n = 798 cases) and control participation was 71%
(n = 843 controls). All subjects provided written,
informed consent and the protocol was reviewed by the
Mayo Clinic Institutional Review Board.
Mammographic density measurement
Mammograms were only ascertained on controls for this
analysis, as the focus of the study was to understand the
genetics of mammographic density among healthy
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women. The closest screening mammogram to enroll-
ment date (median 0 days, 59% were same day, 82%
within 1 year) was obtained and digitized on a Kodak
Lumiscan 75 scanner (LS 75) (Lumisys/Eastman Kodak
Co, Rochester, New York, USA) with 12-bit grayscale
pixel depth for 686 of the 843 (81%) control women;
analyses focused on the 484 mammograms (of 579 post-
men eligible or 84%) from postmenopausal Caucasian
women due to the composition of the SASBAC replica-
tion study. We estimated mammographic density using
the cranial-caudal (CC) or top-down view from the left
breast using a validated computer-assisted thresholding
program (Cumulus [39] University of Toronto, Toronto,
Ontario, Canada) that we have used in previous reports
[40-42] and has been shown by our group to predict
breast cancer [43]. We assessed percent mammographic
density defined as the absolute area of dense tissue on
the mammogram divided by the total area multiplied by
100. All images were read by one trained technician
who consistently maintained high reliability (r > 0.90)
while reading duplicate images across varying time
frames [41,43].
Gene and SNP selection
We identified genes encoding proteins involved in regu-
lation of all aspects of cell division, identified through the
literature and known pathways. Specifically, we chose
genes implicated in mitotic entry, mitotic progression,
the mitotic checkpoint, cytokinesis and mitotic exit. In
addition, we included genes implicated in mitotic func-
tion through functional screens [44,45] and genes
involved in the structure and function of centrosomes
[46], which are directly involved in chromosome segrega-
tion. SNPs representing common genetic variation within
these 378 genes were identified and examined with per-
cent mammographic density. SNP selection has been
described in detail elsewhere [38,46]. Briefly, we first
selected tagSNPs (r2 > 0.80) from SNPs with MAF ≥ 0.05
located within 5 kb of the largest cDNA isoform (genome
build 35) to represent a reduced set of SNPs in each gene
[47]. We prioritized putative functional SNPs (within 1
kb upstream, 5’ UTR, 3’ UTR or non-synonymous) with
MAF ≥ 0.05 identified in Ensembl version 34. A total of
2,058 SNPs in 378 genes were identified.
As detailed elsewhere [38], samples from both cases
and controls, (including 5% duplicate samples), were
assayed at Illumina Corporation (San Diego, CA, USA)
on an Illumina BeadLab using the Illumina GoldenGate
Assay™. DNA activation, incubation with assay oligonu-
cleotides, PCR amplification and analysis using the
BeadStudio software for automated genotype clustering
and calling was performed according to a standard pro-
tocol [48-50]. Successful genotyping was achieved for
99.9% of DNA samples (seven case DNAs failed).
Analyses of SNPs with mammographic density were lim-
ited to postmenopausal controls. We assessed depar-
tures from Hardy-Weinberg equilibrium (HWE) (P <
0.001) in these 484 postmenopausal control subjects
using a Pearson goodness-of-fit test. Of the 2,058 SNPs
genotyped, 2,048 (99.5%) were in HWE, and SNP call
rates were > 99% in 2,041 SNPs (2,053 SNPs > 98%).
Also, only 24 (5%) of the 484 had sample call rates
below 98%, but these were all above 95%.
SASBAC study
The Singapore and Sweden Breast Cancer Study (SAS-
BAC) is a population-based case-control study of post-
menopausal breast cancer in women aged 50 to 74 years
born in Sweden. Details on data collection and subjects
have been described previously [51]. Controls were
white Europeans randomly selected from the Swedish
population and frequency matched to the expected age
distribution of cases and on geographical area. They
served as the replication sample for this study. The final
study group with both mammographic density and gen-
otype data included 726 controls of 764 eligible (95%).
Approval of the study was given by the ethical review
board at the Karolinska Institute (Stockholm, Sweden)
and six other ethical review boards in the respective
regions in which the subjects were based.
Screening film mammograms corresponding to the
enrollment date were obtained. The medio-lateral obli-
que (MLO) view was digitized using an Array 2905HD
Laser Film Digitizer (Array Corporation, Roden, The
Netherlands, which covers a range of 0 to 4.7 optical
density. Similar to the MCBCS, the Cumulus software
was used for determination of percent mammographic
density on a randomly selected side. A random 10% of
the images were included as replicates to assess the
intra-observer reliability, which was high with a Spear-
man rank correlation coefficient of 0.95.
Associations of any SNP with P < 0.05 in MCBCS by
the log-additive test were attempted for in silico replica-
tion within SASBAC using available genotype informa-
tion from a genome wide association study (GWAS) of
breast cancer [52]. Briefly, 764 controls were genotyped
on the HumanHap550 BeadChip; of these, 726 (95%)
controls had films available. When the exact SNP was
genotyped and available as part of the SASBAC GWAS
(which occurred 56% of the time), the corresponding P-
value for that SNP was used. If the exact SNP was not
available, we examined the association with available
SNPs in high linkage disequilibrium (LD), defined as r2
> 0.70 with the SNP of interest, using HapMap CEU.
Mammographic density comparison studies
We compared the similarity of percent mammographic
density (PMD) assessment between the readers from
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MCBCS and SASBAC using a standard set of 20 film
mammogram images across varying densities. The intra-
reader reliability assessed as the intraclass correlation or
ICC for PMD between readers was high (ICC = 0.99;
Figure 1). We also assessed the intraclass correlations
between our readers with Dr. Norman Boyd, an expert
in the estimation of density and found strong agreement
(ICC = 0.98 and 0.99 for MCBCS and SASBAC, respec-
tively, Figure 1).
Further, since MCBCS and SASBAC ascertained and
estimated PMD from different mammogram views (CC
vs. MLO, respectively), we were interested in the differ-
ences in PMD between the two mammogram views. A
previous study of 30 women found strong correlations of
CC and MLO views (between 0.86 and 0.96), suggesting
representative information is provided in a single view
[53]. We conducted a larger study of 700 controls with
both right and left CC and MLO views [43]. We exam-
ined the differences in mean PMD as well as Pearson cor-
relations (r) assessed from the CC and MLO views from
the same breast. We found the average absolute differ-
ence in PMD between CC and MLO views to be 2.0%
(SD = 6.5) for the left and 2.2% (SD = 6.4%) for the right
breast. The Pearson correlations between the PMD from
CC and MLO were also very high, with r = 0.90 for both
left and right breasts (Figure 2).
Statistical analysis
Primary analyses focused on the 484 postmenopausal
controls in the MCBCS study, since SASBAC was
Figure 1 Comparison of percent mammographic density estimation among MCBCS, SASBAC, and expert readers.
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comprised only of postmenopausal women. Initially, we
examined the distribution of risk factors and mammo-
graphic density among postmenopausal controls from
MCBCS and SASBAC. Genotypes from controls were
used to estimate allele frequencies within each study set.
Individual SNP associations with PMD were assessed
using linear regression. No transformation of PMD
was made in MCBCS since residuals were approxi-
mately normal. Tests for associations were carried out
assuming an ordinal (log-additive or additive) genoty-
pic relationship using simple tests for trend within the
linear regression models. All analyses were adjusted for
age, body mass index (BMI) and current post-meno-
pausal hormone (PMH) use. Examination of transfor-
mations of BMI and age did not result in substantial
improvement in model fit when compared to models
that were based on the original scale of these covari-
ates. Because of this, and because linear regression
assumptions were met in the analysis models, the ori-
ginal scale for these variables was used in all analyses
on MCBCS data.
Similar analyses were performed for the replication of
SNPs in the SASBAC sample with PMD, although a
square root transformation of PMD was required to
meet linear regression assumptions. Analyses were
adjusted as above. Mean PMD from SASBAC was back-
transformed for each genotype within the context of the
general model in order to more directly compare results
to those from MCBCS.
A pathway-level analysis was conducted using the self-
contained gene-set analysis method, GLOSSI [54]. This
algorithm, based on Fisher’s combined probability test,
is designed to determine if the distribution of P-values
in a set of genes deviates from what is expected based
on the null hypothesis of no association. GLOSSI was
implemented using 2,028 SNPs from the 378 genes
among the 484 postmenopausal breast cancer-free con-
trols in the MCBCS study to test for an association with
this pathway and PMD adjusted for age, BMI and PMH
use as above. A pathway-level P-value was obtained
based on 500 permutations.
To assess heterogeneity of associations by study, a
meta-analysis was performed on the ordinal parameter
estimates and the Q-test was calculated [55]. In order to
make the ordinal estimates comparable between studies
for the meta-analysis, ordinal estimates for the MCBCS
sample were estimated using square root transformed
percent density within this sample. These parameter
estimates were used to calculate the Q-test statistic and
resulting heterogeneity P-value.
In order to set a threshold for statistical significance
that appropriately reflects the number of SNPs tested,
recognizing that SNPs within genes may not be inde-
pendent, we calculated an effective number of
Figure 2 Comparison of percent mammographic density estimation on MLO vs. CC views from 700 controls [43].
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independent tests within each gene using an eigenvalue
based measure as proposed by Galwey [56]. We
summed the effective number of independent tests per
gene across all genes in the study to estimate the effec-
tive number of independent tests (n = 1,178 for stage I
and n = 64 for replication). We use this result to set our
threshold for significance via a Bonferroni correction for
the number of independent tests (0.05/1,178 = 4.2 × 10-
5 for stage I and 0.05/64 = 7.8 × 10-4 for replication).
Analyses were implemented using SAS (SAS Institute,
Cary, NC, USA, Version 8, 1999), S-Plus (Insightful
Corp, Seattle, WA, USA, Version 7.05, 2005) and R soft-
ware systems.
Results
The 2,058 SNPs from 378 genes were examined for
associations with PMD among 484 postmenopausal
women within MCBCS. Characteristics of the MCBCS
postmenopausal controls are described in Table 1. One
variant, rs10733604 in PRPF4, was associated with
adjusted PMD (P = 2.7 × 10-7). A second, albeit not sta-
tistically significant, association was seen with
rs12563929 in PRKACB (P = 2.2 × 10-4) (Additional file
1). In total, we found 88 SNPs in 58 genes associated at
P < 0.05 with percent density. These SNPs were selected
for examination within the SASBAC study (Additional
file 1). The pathway analysis incorporating all 378 genes
showed no evidence of enrichment in the number of
associations observed between SNPs in the mitotic
genes and PMD (P = 0.60).
The 726 controls from SASBAC were slightly younger
(mean age 62.8 ± 6.2 vs. 63.6 ± 9.2), less likely to use
PMH (38.7% vs. 65.3%) and had lower average BMI
(25.7 vs. 26.9) and PMD (14.4% vs. 18.6%) than the
MCBCS controls (Table 1). Both studies showed inverse
associations of age and BMI with PMD and positive
associations with current PMH use (Table 2).
Within SASBAC, genotype information was available
for 73 of the 88 SNPs (located in 51 genes) associated
with PMD at P < 0.05 in MCBCS. Of these, 56% were
the exact SNP but the remainder were SNPs in moder-
ate to high linkage disequilibrium (LD > 0.70) with the
SNP of interest within MCBCS. Both of the SNPs
rs10733604 in PRPF4 and rs12563929 in PRKACB were
available in SASBAC (noted in Additional file 1).
There were no associations of rs10733604 (P = 0.23)
or rs12563929 (P = 0.93) with percent density in the
SASBAC study. Eight of the 73 (10.9%) candidate SNPs,
located in seven genes, displayed associations also at P <
0.05 with PMD in the SASBAC study (Table 3),
although none reached the statistical threshold. Only
variants in LOC375190 (rs2080727) AURKB (rs4792590
and rs3027260, LD of r2 = 0.71) and MCM3
(rs3765447), showed consistent direction of effect in
both the MCBCS and SASBAC studies, which was also
reflected in the tests of heterogeneity (Table 3).
Discussion
Overall, we found no statistically significant associations
between SNPs involved in mitosis with percent





N % or mean N % or mean
Age, years 40 to 49 26 5.4 1 0.1
50 to 59 157 32.4 237 32.6
60 to 69 176 36.4 363 50.0
70+ 125 25.8 125 17.2
Body mass index, kg/m2 Mean (SD) 464 26.9 (5.3) 718 25.7 (4.1)
Postmenopausal hormone use Current 153 31.6 95 13.1
Former 163 33.7 186 25.6
Never 136 28.1 362 49.9
Unknown 32 6.6 83 11.4
Percent Mammographic Density, (%) Mean (SD) 484 18.6 (13.9) 726 14.4 (13.9)
Categories 0 30 6.2 45 6.2
1 to 9 116 24.0 324 44.6
10 to 24 201 41.5 225 31.0
25 to 49 125 25.8 111 15.3
50 to 74 11 2.3 21 2.9
75+ 1 0.2 0 0
aMayo Clinic Breast Cancer Study. bSingapore and Sweden Breast Cancer Study.
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mammographic density. There were consistent associa-
tions (albeit only at a significance of P < 0.05) among
four SNPs in three genes involved in either cell division
(AURKB AND LOC375190) or cellular proliferation
(MCM3) and adjusted percent density among two stu-
dies of postmenopausal women. These associations war-
rant further investigation.
Strengths of this study include examination of a novel
pathway with adjusted percent mammographic density,
SNP associations examined in two independent popula-
tions, similar quantitative measures of density used in
both studies, adjustment for potential confounding fac-
tors, and focus on the homogenous subgroup of post-
menopausal, healthy women. Also, non-replication of
associations in the SASBAC study did not appear to be
due to systematic differences in the readers’ perfor-
mance or mammogram view assessed, as our compari-
son studies suggested estimates were similar for both
readers across a common set of images as well as by
MLO vs. CC views. However, limitations include inabil-
ity to confirm associations for 15 SNPs and use of dif-
ferent digitizers that could potentially add systematic
bias to the percent density estimation.
Although very little is known about the biology under-
lying mammographic density, evidence strongly suggests
that genes contribute to a large proportion of the varia-
tion in density [3,4,7,9]. To date, replicated associations
between genetic variants associated with a few candidate
genes, including IGF-1, ESR1, HSD3B1, and COMT and
breast density have been observed, implicating primarily
pathways that regulate steroid hormone synthesis and
metabolism, hormone receptors and proliferative path-
ways, including the insulin-like growth factor pathway
[6]. Our study is the first to perform a comprehensive
analysis of candidate genes in mitosis. However, our
results do not suggest a strong role of genes involved in
mitosis with percent mammographic density.
Interestingly, two of the genetic loci (AURKB,
LOC375190) containing SNPs that displayed consistent,
albeit nonsignificant, associations with adjusted percent
mammographic density in the MCBCS and SASBAC
studies, have been implicated in the regulation of the
metaphase to anaphase transition during chromosome
segregation. Although little is known about the protein
encoded by LOC375190, a functional siRNA based
screen has shown that reduced levels of LOC375190
causes severe spindle defects and mitotic arrest and sub-
sequent formation of polyploid cells due to premature
mitotic exit [44]. In contrast, much is known about the
role of the AURKB-encoded Aurora B protein in mitotic
regulation. While Aurora B has been implicated in mito-
tic entry and also in cytokinesis and mitotic exit, the
primary role for this kinase is in the assembly of factors
involved in spindle attachment and tension and regula-
tion of the mitotic checkpoint. Loss or gain of Aurora B
results in defects in the metaphase to anaphase transi-
tion and subsequent aneuploidy due to chromosome
segregation defects or polyploidy due to premature
mitotic exit. Interestingly, Aurora B is localized at cen-
trosomes during mitosis and may influence spindle
growth from the centrosome to the kinetochore during
mitosis, similar to LOC375190, resulting in defects in
chromosome segregation and/or premature mitotic exit
[57]. Given these common functions, it is tempting to
speculate that common genetic variation in these two
loci may result in defects in chromosome segregation,








Mean 95% CI Mean 95%CI
Age, years 40 to 49 23.6 18.3 to 28.9 8.2 —————
50 to 59 20.1 17.9 to 22.2 16.7 14.9 to 18.6
60 to 69 18.2 16.1 to 20.2 13.7 12.4 to 15.1
70+ 16.4 14.0 to 18.8 12.0 9.5 to 14.5
Body mass index, kg/m2b < 25 24.8 24.0 to 27.6 19.2 17.5 to 20.8
25 to 30 16.0 14.2 to 17.9 11.2 10.0 to 12.5
> 30 10.6 8.2 to 13.0 6.8 5.1 to 8.5
Unknown 15.9 10.2 to 21.5 10.5 3.9 to 17.2
Postmenopausal hormone usec Current 21.9 19.8 to 24.0 19.6 16.4 to 22.7
Former 18.1 16.1 to 20.2 17.0 14.9 to 19.1
Never 15.6 13.4 to 17.9 11.7 10.6 to 12.8
Unknown 18.3 12.7 to 23.9 14.7 11.8 to 17.6
aMayo Clinic Breast Cancer Study; Singapore and Sweden Breast Cancer Study.
b Adjusted for age. cAdjusted for age and BMI.
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premature mitotic exit and an increase in the number of
cells with multiple nuclei.
Since non-epithelial nuclear area, which may represent
increased nuclear size due to failed or delayed cell divi-
sion, has been associated with mammographic breast
density in women over age 50 [37], studies of cell divi-
sion in dense and non-dense mammary tissues may pro-
vide further insight into the associations reported here.
However, since these proteins are multifunctional and
may influence other cellular processes, including growth
factors [58], alternative explanations for the associations
with density must also be considered.
The third locus of interest, a variant in mini-chromo-
some maintenance complex component 3 or MCM3,
however, plays a role in cellular proliferation. The pro-
tein encoded by MCM3 is one of the highly conserved
mini-chromosome maintenance proteins (MCM) that
are involved in the initiation of genome replication. The
Table 3 Polymorphisms in mitotic pathway genesa and percent mammographic density among MCBCSb (n = 484) and
SASBACb(n = 726) controls.
MCBCS SASBAC
Chr Gene Name Effect SNP Position (bp) N PMD
Est (SE)/
adj meanc
P-valued N Sqrt PMD Est (SE)/
adj meane
P-valued P-Hetf
1 GALNT2 Ordinal rs1043908 228483917 484 2.88 (1.28) 0.025 725 -0.314 (0.135) 0.02 < 0.001
A/A 373 17.9 555 19.0
A/G 102 20.8 158 16.3
G/G 9 23.6 12 13.9
2 LOC375190 Ordinal rs2080727 24204411 484 1.69 (0.85) 0.048 725 0.185 (0.095) 0.05 0.54
A/A 195 17.2 305 17.1
A/G 215 19.4 332 18.7
G/G 74 20.2 88 20.3
6 MCM3 Ordinal rs3765447 52249471 483 3.62 (1.76) 0.040 725 0.45 (0.188) 0.017 0.96
A/A 422 18.2 644 17.7
A/G 60 22.3 76 21.7
G/G 1 12.7 5 26.1
8 TNKS Ordinal rs12549064 9479437 484 -2.15 (1.09) 0.048 725 0.321 (0.116) 0.006 0.001
A/A 303 19.5 496 17.8
A/C 166 17.4 205 20.6
C/C 15 15.1 24 23.6
10 KIF11 Ordinal rs2275220 94362686 484 -4.23 (2.12) 0.046 726 0.45 (0.172) 0.009 0.005
A/A 448 19.0 613 17.9
A/G 34 13.5 111 22.0
G/G 2 20.4 2 26.4
11 STIM1 Ordinal rs3794050 4068476 484 2.85 (1.38) 0.039 726 -0.383 (0.142) 0.007 0.003
G/G 389 17.8 547 19.4
G/A 89 23.0 173 16.2
A/A 6 8.6 6 13.3
17 AURKB Ordinal rs3027260 8053911 484 -3.33 (1.52) 0.029 726 -0.404 (0.177) 0.022 0.73
G/G 404 19.2 632 18.7
G/A 77 15.8 91 15.4
A/A 3 12.8 3 12.4
Ordinal rs4792590 8057840 484 -3.14 (1.34) 0.020 726 -0.39 (0.152) 0.010 0.89
G/G 377 19.3 597 18.6
G/A 102 16.6 121 15.4
A/A 5 9.5 8 12.5
aP ≤ 0.05 in both studies. bMayo Clinic Breast Cancer Study; Singapore and Sweden Breast Cancer Study.
cPMD Est(SE): ordinal parameter estimate and standard error reflecting the estimated change in percent density per each additional copy of the minor allele
carried. Adjusted mean from general model: least squares estimate of mean percent density for each genotype, adjusted for age, BMI, and PMH. dP-value from
analyses adjusted for age, BMI, and PMH. eSqrt PMD Est(SE): ordinal parameter estimate and standard error reflecting the estimated change in percent density
error per each additional copy of the minor allele carried. Adjusted mean from general model: least squares estimate of mean percent density for each genotype,
adjusted for age, BMI, and PMH. Least squares means back transformed from square root to original scale. fP-value from test for heterogeneity from meta-
analysis performed on the ordinal parameter estimates (ordinal estimates for the MCBCS sample were estimated using square root transformed PMD).
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acetylation of this protein inhibits the initiation of DNA
replication and cell cycle progression. Proliferation of
stroma and/or epithelium has been hypothesized to
underlie increased mammographic density [11], although
few studies have shown positive associations between
proliferation markers and PMD [24,26,27,59] or tissue
from dense areas of the breast [28].
Conclusion
In summary, we present the first report of variation in
genes involved in regulation of cell division and mam-
mographic density. We find no strong evidence of asso-
ciation between variants in genes involved in mitosis
and adjusted percent mammographic density; however,
further investigation of variants in AURKB, LOC375190
and MCM3 is warranted.
Additional material
Additional file 1: Associations between variants in genes in the
mitotic pathway and percent mammographic density (PMD) in two
studies of postmenopausal women.484 Caucasian subjects from the
Mayo Clinic Breast Cancer Study (MCBCS, 2001 to 2005) and 726
Caucasian subjects (controls) from Singapore and Sweden Breast Cancer
Study (SASBC, 1993-1995).
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